| 7.76 -0.12 (-1.52%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.72 | 1-year : | 11.36 |
| Resists | First : | 8.32 | Second : | 9.72 |
| Pivot price | 7.01 |
|||
| Supports | First : | 6.73 | Second : | 5.75 |
| MAs | MA(5) : | 7.53 |
MA(20) : | 6.8 |
| MA(100) : | 4.62 |
MA(250) : | 2.66 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 82.9 |
D(3) : | 82.9 |
| RSI | RSI(14): 71.3 |
|||
| 52-week | High : | 8.32 | Low : | 0.71 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STTK ] has closed below upper band by 10.8%. Bollinger Bands are 36.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.96 - 8 | 8 - 8.03 |
| Low: | 7.59 - 7.65 | 7.65 - 7.68 |
| Close: | 7.68 - 7.76 | 7.76 - 7.82 |
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Sun, 12 Apr 2026
Shattuck Labs (STTK) price target increased by 37.93% to 10.20 - MSN
Wed, 08 Apr 2026
Shattuck Labs (NASDAQ: STTK) seeks approval of revamped equity plan at 2026 virtual meeting - Stock Titan
Sat, 04 Apr 2026
STTK Should I Buy - Intellectia AI
Fri, 06 Mar 2026
Why Shattuck Labs Stock Soared More Than 53% Higher This Week - The Motley Fool
Thu, 05 Mar 2026
Shattuck Labs 10-K: $1.0M Revenue, $(0.70) EPS on FY Loss Improvement - TradingView
Thu, 05 Mar 2026
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 4.757e+007 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 1,600 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.774e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 142.6 % |
| Return on Equity (ttm) | -35.4 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -46.71 |
| EBITDA (p.s.) | -1.51163e+006 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.17 |
| Price to Cash Flow | 7.7 |
| Dividend | 0 |
| Forward Dividend | 1.47e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|